Allosteric inhibitor of Bcr-Abl tyrosine kinase activity (IC50
= 267 nM); inhibits proliferation and induces apoptosis in Bcr-Abl-expressing cells. Selective for Bcr-Abl over a panel of serine, threonine and tyrosine kinases. Non-ATP-competitive.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Targeting Bcr-Abl by combining allosteric with ATP-binding site inhibitors.
Zhang et al.
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián et al.
Inhibitors of Bcr-abl... breaking new ground again.
Ohren & Sebolt-Leopold et al.